In humans, the most frequent genetic alteration that underlies PDAC is an activating mutation of the KRAS oncogene (see Box 1), which occurs in >90% of tumours (Almoguera et al., 1988; Biankin et al., 2012). The gene discussed is KRAS; the disease is neoplasm.